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Abstract
Background: Recent data suggest that anti-TNF doses can be reduced in ankylosing spondylitis (AS) patients. Some
authors even propose withdrawing treatment in patients in clinical remission; however, at present there is no
evidence to support this.
Objective: To assess how long AS patients with persistent clinical remission remained free of flares after anti-TNF
withdrawal and to evaluate the effects of treatment reintroduction. We also analyze the characteristics of patients
who did not present clinical relapse.
Methods: Multicenter, prospective, observational study of a cohort of patients with active AS who had received
infliximab as a first anti-TNF treatment and who presented persistent remission (more than 6 months). We recorded
at baseline and every 6–8 weeks over the 12-month period the age, gender, disease duration, peripheral arthritis or
enthesitis, HLA-B27 status, BASDAI, CRP, ESR, BASFI, and three visual analogue scales, spine global pain, spinal night
time pain, and patient’s global assessment.
Results: Thirty-six out of 107 patients (34%) presented persistent remission and were included in our study. After
treatment withdrawal, 21 of these 36 patients (58%) presented clinical relapse during follow-up. Infliximab therapy
was reintroduced and only 52% achieved clinical remission, as they had before the discontinuation of infliximab; in
an additional 10%, reintroduction of infliximab was ineffective, obliging us to change the anti-TNF therapy. No
clinical or biological factors were associated with the occurrence of relapse during the follow-up.
Conclusions: Two thirds of patients in clinical remission presented clinical relapse shortly after infliximab
withdrawal. Although the reintroduction of infliximab treatment was safe, half of the patients did not present the
same clinical response that they had achieved prior to treatment withdrawal.
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Background
Axial spondyloarthritis (axSpA) comprises a group of
chronic, immune-mediated inflammatory diseases char-
acterized by the predominance of inflammation in the
sacroiliac joints and spine. Involvement of peripheral
skeletal sites and extra-articular manifestations, such as
uveitis, psoriasis, or inflammatory bowel disease (IBD),
may develop during the course of the disease [1].
Ankylosing spondylitis (AS) is the most representative
disease in this group; its burden has recently been recog-
nized as severe, frequently leading to invalidity, work
loss, and social impairment [1, 2].
The introduction of biological therapy has undoubt-
edly been an important step forward in improving the
quality of life, activity, functionality, metrology, and most
extra-articular manifestations in patients with AS and
other forms of spondyloarthropathy [1]. Around 60% of
patients treated with an anti-TNF achieve a good clinical
response; however, according to the Assessment of
Spondyloarthritis International Society (ASAS), only 20–
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30% achieve criteria of clinical partial remission in which
the patient is apparently asymptomatic [3, 4].
Data from uncontrolled studies and from clinical prac-
tice support the possibility of reducing anti-TNF doses
below the normal levels licensed in AS patients with
good clinical response, and especially in patients in clin-
ical remission [5–7]. In this sense, a recent consensus
paper from the Spanish Society of Rheumatology and
the Spanish Society of Hospital Pharmacy [8] stressed
the possibility of withdrawing anti-TNF treatment in
some patients who maintain good clinical response after
intensive reduction of anti-TNF treatment [8], but the
evidence supporting this recommendation is lacking.
In this sense, previous classic studies have suggested the
need to maintain anti-TNF therapy indefinitely, as the with-
drawal of this treatment is associated with disease reactiva-
tion in around 90% of patients within 12months,
independently of the anti-TNF used or the previous dur-
ation of treatment [9]. The factors associated with these
reactivations include the high clinical activity at the time of
treatment suspension, especially when measured through
C-reactive protein (CRP), as well as age and disease dur-
ation [9]. However, the heterogeneity of the clinical symp-
toms of the AS patients included the different drugs and
doses of anti-TNF prescribed prior to the withdrawal of the
treatment and especially the lack of homogeneous criteria
of clinical remission in the different studies published all
mean that the issue remains highly controversial.
More recently, data from a multicenter, randomized,
double-blind study in patients with non-radiographic
axSpA, who initially achieved sustained remission,
showed that continued therapy with adalimumab was as-
sociated with a significant maintenance of remission
compared with treatment withdrawal [10].
Since anti-TNF treatment also presents drawbacks,
such as its high cost and the possibility of long-term side
effects, it seems reasonable to plan a time-limited treat-
ment for some patients. The aim of our study was to
analyze the consequences of the clinical decision to
withdraw anti-TNF treatment in a very homogeneous
group of AS patients. In this study, we included only
data from AS patients who received infliximab as a first
anti-TNF treatment and who presented persistent clin-
ical remission (at least 6 months) in accordance with our
pre-established definition [11]. The focus of the study
was to assess how long patients maintained a good clin-
ical response defined as the absence of flare after
anti-TNF withdrawal, and to define the characteristics of
patients who did not present clinical relapse.
Methods
We conducted a prospective observational study in 23
hospitals with Rheumatology Services in Catalonia,
north-eastern Spain, a region with seven million
inhabitants. The study included a cohort of patients with
active AS who had received infliximab as a first
anti-TNF treatment. The study was authorized by the
Ethics Committee of the participating hospitals, and all
patients gave informed consent prior to taking part in
the study.
Patients were included in the cohort and started inflix-
imab treatment if they were aged 18 or over, had a diag-
nosis of AS according NY criteria, presented a disease
duration longer than 1 year, and fulfilled criteria for
anti-TNF treatment according to the Guidelines of the
Spanish Society of Rheumatology (SER) (BASDAI ≥ 4,
despite treatment with 2 nonsteroidal anti-inflammatory
drugs (NSAID) for a minimum of 3 months at full dose)
[12]. After the infliximab induction period, all patients
who presented persistent clinical remission (BASDAI ≤
2, normal CRP, and absence of active arthritis and/or
enthesitis and/or any other extra-articular manifestation
during the last 6 months in the absence of any additional
steroid and/or NSAID treatment) were included in a
prospective study of infliximab withdrawal. Patients with
any other definitive diagnosis of spondyloarthritis (psori-
atic arthritis, inflammatory bowel disease, or reactive
arthritis) were excluded, as were those with any con-
comitant rheumatic disease that might modify the clin-
ical evaluation of the disease activity.
During the study, in accordance with standard clinical
practice, we prospectively recorded the following vari-
ables at baseline, and every 6–8 weeks over a follow-up
period of 12 months: age, gender, disease duration, the
presence and number of peripheral arthritis or enthesi-
tis, the presence of HLA-B27, the BASDAI (Bath Anky-
losing Spondylitis Disease Activity Index), CRP,
erythrocyte sedimentation rate (ESR), Bath Ankylosing
Spondylitis Functional Index (BASFI), and three visual
analogue scales (VAS), spine global pain, spinal night
time pain, and patient’s global assessment. In the
pre-study phase, as a secondary objective, we also retro-
spectively recorded the data from all the cohort of pa-
tients with active AS who had initiated treatment with
infliximab.
Clinical relapse was defined in any time period as
newly appearing BASDAI ≥ 4 and/or PCR ≥ 0.8 mg/dl.
For patients with relapse after treatment withdrawal,
infliximab treatment was reintroduced without an induc-
tion phase or any previous premedication. At the end, a
final visit was performed in all patients included in the
study.
Frequencies and percentages were given for subjects
who achieved initial remission after infliximab treatment
and for subjects who did not present a clinical flare after
treatment withdrawal during follow-up. Other parame-
ters including baseline and clinical data during follow-up
were described by frequency and percentage, mean and
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standard deviation (SD), median and 25 and 75 percen-
tiles, and 95% confidence intervals [95%CI], as appropri-
ate. No inferential analysis was conducted.
Results
One hundred and seven patients, 72% male, with a first
infliximab prescription, were retrospectively identified.
The main characteristics of these patients are shown in
(Table 1). Among these patients, 36 (34%) achieved per-
sistent clinical remission and were included in the pro-
spective study, so infliximab treatment was then
discontinued. The period of clinical remission before
treatment withdrawal ranged in all cases between 6 and
12months. After treatment withdrawal, only 12 out of
these 36 subjects (33.3%) remained free of clinical re-
lapse during the follow-up. Overall, 21 of these 36 pa-
tients (58.3%) presented clinical relapse (three patients
were lost during the follow-up study). Half of the re-
lapses appeared within 6 months of infliximab with-
drawal. In the 21 patients who presented clinical relapse,
infliximab therapy was reintroduced and 11 (52%) again
achieved clinical remission, but ten (48%) did not. Of
these ten patients, in seven, the reintroduction of inflixi-
mab was associated with good clinical response (absence
of flare, BASDAI < 4 and/or CRP < 0.8 mg/dl), but in
three (14%), the treatment was ineffective, and we had to
change to another anti-TNF treatment (Fig. 1). The re-
introduction of infliximab was safe, and no important
side effects or infusion reactions were recorded.
Analyzing the retrospective data, we found that age
(39 ± 12 vs 43 ± 14 years, p = 0.05), disease duration (9 ±
8 vs 14 ± 11 years, p = 0.02), and CRP at the start of
infliximab treatment (3.41 ± 3.65 vs 1.63 ± 2.10, p = 0.02)
were associated, in the pre-study period, with clinical re-
mission under infliximab treatment. However, unfortu-
nately, we did not find any statistical differences
between any clinical or biological parameter in patients
who remained free of clinical relapse during follow-up
after treatment withdrawal compared with those who
did not (Table 2).
Discussion
This is the first prospective study to show that the ma-
jority of longstanding AS patients in persistent clinical
remission presented clinical relapse after infliximab
withdrawal within the following 12 months. Moreover,
although the reintroduction of infliximab was safe and
effective in most cases, around half of the patients did
not achieve remission after treatment reintroduction and
in an additional 10% the treatment was ineffective, obli-
ging us to change the prescription.
Data from clinical practice and registries have sug-
gested that in patients with sustained clinical remission
(i.e., more than 6months), reducing the treatment dose
may be a desirable therapeutic goal [5–7]. For example,
the recent EULAR guidelines [13] incorporate the taper-
ing of biological therapy for these patients as a new rec-
ommendation, even though the data supporting this
policy are limited due to the absence of randomized
controlled studies. Recently our group have been com-
municated a randomized pragmatical study demonstrat-
ing the no inferiority of a regime of dose reduction
compared with full doses in these patients [14].
Many previous studies have suggested that treatment
withdrawal in AS patients leads to a reactivation of the
disease [8, 15–17]. Nonetheless, in most studies,
Table 1 Baseline characteristics of the cohort of 107 patients who started infliximab treatment
Number of valid values Baseline characteristics
Age (years), mean ± SD 104 41.8 ± 12.0
Disease duration (years)†, mean ± SD
male sex, n (%)
HLA-B27 positive, n (%)
91,107 77 11.9 ± 10.4
75 (70.1%)
69 (89.6%)
Modified Schober test (cm), mean ± SD 87 3.7 ± 1.9
Fingertip to floor distance (cm), mean ± SD 101 19.6 ± 13.9
Number of swollen joints¸ mean ± SD 107 1.13 ± 2.2
CRP (mg/dl), mean ± SD 103 2.23 ± 2.82
ESR (mm/h), mean ± SD 105 35.3 ± 28.0
VAS nocturnal spinal pain (cm), mean ± SD 99 5.7 ± 2.8
VAS spinal pain(cm), mean ± SD 98 6.3 ± 2.4
VAS patient global (cm), mean ± SD 99 7.2 ± 1.8
BASDAI score (cm), mean ± SD 102 6.2 ± 1.9
BASFI score (cm)¸ mean ± SD 100 4.9 ± 2.7
n number, SD standard deviation, CRP C-reactive protein, ESR erythrocyte sedimentation rate, VAS patient’s rating of pain by visual analogue scale ranging from 0
(none) to 10 (worst), BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index
†50% of patients had less than 10 years of disease duration
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Fig. 1 Flow chart of the patient outcomes included in the REMINEA study. Clinical persistent remission: BASDAI ≤ 2 and normal C-protein reactive
(CRP) and the absence of active arthritis and/or enthesitis and/or any other extra-articular manifestation during the last 6 months in the absence
of any additional steroid and/or NSAID treatment. Relapse: any time period as newly appearing BASDAI ≥ 4 and/or CRP ≥ 0.8 mg/dl. Good clinical
response: BASDAI< 4 and/or CRP < 0.8 mg/dl. Asterisk indicates 3 patients in the study phase of 12 months of follow-up were lost to follow-up
Table 2 Comparison of significant variables between patients on infliximab according to remission status and patients after
infliximab withdrawal according to the absence of clinical relapse





P value Clinical relapse**
(n = 21)
Free of clinical
relapse (n = 12)
P value
Age (years), mean ± SD 38.52 ± 11.96 3.39 ± 11.81 0.05 40 ± 12 37 ± 12 ns
Disease duration (years)†,
mean ± SD
8.94 ± 8.09 13.69 ± 11.29 0.02 9 ± 8.0 9 ± 9.0 ns
CRP (mg/dl), mean ± SD 3.41 ± 3.65 1.63 ± 2.10 0.01 3.9 ± 3.5 3.0 ± 3.1 ns
BASDAI score (cm), mean ± SD 5.95 ± 1.85 6.4 ± 1.82 ns 6 ± 2.0 6 ± 2.0 ns
BASFI score (cm)¸ mean ± SD 4.35 ± 2.44 5.18 ± 2.81 ns 4 ± 3.0 5 ± 2.0 ns
SD standard deviation, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index
*Clinical persistent remission: BASDAI ≤ 2 and normal C-protein reactive (CRP) and the absence of active arthritis and/or enthesitis and/or any otherextra-articular
manifestation during the last 6 months in the absence of any additional steroid and/or NSAID treatment, refers to patients under IFX treatment
**Relapse: any time period as newly appearing BASDAI ≥ 4 and/or CRP ≥ 0.8 mg/dl after treatment with IFX withdrawal
†50% of patients had less than 10 years of disease duration
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withdrawal is performed in patients who are not in clin-
ical remission, and some of them even present high CRP
serum levels [15, 16]. Recently, a controlled and ran-
domized study in non-radiographic axSpA patients re-
ported in patients who achieved sustained remission
with adalimumab more reactivation of the disease in the
treatment withdrawal compared with the control arm
(patients without suspension of anti-TNF) [10]. How-
ever, some official recommendations, based only on clin-
ical practice and in the expert opinion, suggest the
possibility of withdrawing treatment in AS patients with
persistent clinical remission after a notable reduction in
anti-TNF therapy [8, 18].
The data we reported in AS patients were in agreement
with the results previously reported by Landewé et al. in
non-radiographic axSpA [10]. Unfortunately, in our study
as did Landewé et al., the withdrawn of treatment was per-
formed without dose reduction. However, all the patients
previous dose reduction were in persistent remission with-
out any analgesic or anti-inflammatory treatment that
could mask the clinical symptoms.
Few studies are focused on the clinical response to
re-treatment after withdrawal of anti-TNF therapy in pa-
tients with axSpA, suggesting as overall that the reintro-
duction of treatment is comparable to the previously
observed [15, 19, 20]. In contrast, our data indicate that
the reintroduction of biological therapy (without previ-
ous premedication), although it was safe, only half of the
patients achieved clinical remission, as they had before
the discontinuation of anti-TNF. These data are in
agreement with data recently reported by Landewé et al.
in non-radiographic axSpA using adalimumab [10]. Fur-
thermore, in our study, in 10% of the patients, the
re-treatment was ineffective, obliging us to change the
anti-TNF therapy.
The patients we included in the study presented defin-
ite AS and had received only infliximab treatment as
first-line anti-TNF therapy. The baseline characteristics
of our patients are quite similar to those in previous
studies of anti-TNF therapy (22, 23). The baseline clin-
ical characteristics we found to be associated with clin-
ical remission after infliximab treatment—younger age,
short disease duration, and high CRP levels—were in
agreement with the previously published data [21]. Un-
fortunately, a complete study of clinical and biological
factors associated with the presence of relapse during
the following 12 months did not yield any positive re-
sults. The sample size of our study seems to be the main
factor associated with the negative results observed;
however, other larger studies also failed to obtain any re-
sults in this regard [10, 20].
Overall, the results we reported here suggest that the
decision to withdraw treatment should be taken with
considerable caution, and it seems unreasonable to
propose withdrawal as an objective of the treatment
strategy, at least at present, in the absence of any object-
ive predictive factors of persistent clinical remission after
treatment withdrawal.
The study has certain limitations that must be men-
tioned. The sample size is too small to assess factors re-
lated to the persistence of remission or the presence of a
flare after treatment withdrawal; however, other larger
study also failed in this subject [10]. Similarly, since all
the patients were in treatment with infliximab, the re-
sults need to be corroborated in other anti-TNF agents,
but the results published by Landewé et al. [10] using
adalimumab are quite similar. Furthermore, our sched-
ule of treatment did not incorporate a strategy of inflixi-
mab reduction doses before treatment withdrawal, so we
cannot definitively rule out the possibility of withdrawal
treatment in patients under persistent remission after in-
tensive doses reduction. The clinical remission period
before withdrawal of infliximab treatment (6 to 12
months) does not exclude the possibility of some differ-
ent results in patients with a longer period of time in
clinical remission. Finally, the study began before the
publication of the definite new ASAS remission and re-
lapse criteria; however, the criteria applied are widely ac-
cepted and used in the clinical practice.
Conclusion
In summary, this is the first prospective trial performed
in a homogeneous cohort of AS patients to evaluate the
effect of anti-TNF withdrawal in patients presenting per-
sistent clinical remission. Our data of clinical relapse
during the first 12 months in the majority of patients in
AS patients are in agreement with the study in
non-radiographic axSpA previously published. Moreover,
although the reintroduction of infliximab treatment was
safe, half of the patients did not achieve the same clinical
response as prior to treatment withdrawal.
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